Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT00978900
First received: September 16, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted
  Purpose

The purpose of this study is to examine the influence of artificial sweeteners (aspartame, acesulfame K, sucralose) and carbohydrate sugars (glucose, fructose) on the release of gastrointestinal satiety hormones in humans.


Condition Intervention Phase
Healthy
Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
Dietary Supplement: Water
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Carbohydrates and Non Caloric Sweeteners: Differential Effects on Appetite and Secretion of Gastrointestinal Satiety Peptide

Resource links provided by NLM:


Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • Gastrointestinal peptide secretion [ Time Frame: 2 hour blood sampling ] [ Designated as safety issue: Yes ]

Enrollment: 12
Study Start Date: December 2008
Study Completion Date: July 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Acesulfame K Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Active Comparator: Sucralose Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Active Comparator: Aspartame Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Active Comparator: Glucose Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Active Comparator: Fructose Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Placebo Comparator: Water Dietary Supplement: Water

Detailed Description:

Artificial Sweeteners significantly lower energy density of foods and beverages. They are used by diabetics as sugar substitutes as well as by consumers as aids for dietary control. Despite numerous studies which show mainly no influence of artificial sweeteners on glucose metabolism and food intake, discrepancies consist about the real effects of artificial sweeteners. Studies by Blundell and Hill in 1986 have however shown that the consumption of artificial sweeteners resulted in an increase of appetite ratings; the efficiency of AS has therefore been questioned. With respect to the world wide increase in the prevalence in obesity, it seems important to clarify whether artificial sweeteners can help regulate body weight or not. This study will explore the effect of artificial sweeteners on the release of the gastrointestinal satiety hormones PYY, GLP-1, GIP and ghrelin.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subject with a body-mass index of 19.0-24.5
  • Normal eating habits
  • Age 18-40 years
  • Stable body weight for at least three months

Exclusion Criteria:

  • Smoking
  • Substance abuse
  • Regular intake of medications (except for oral contraceptives)
  • Medical or psychiatric illness
  • history of gastrointestinal disorders
  • food allergies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00978900

Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Principal Investigator: Christoph Beglinger, MD Clinical Research Center, University Hospital Basel
  More Information

No publications provided

Responsible Party: Beglinger Christoph, Prof. Dr. med., Department of Gastroenterology, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00978900     History of Changes
Other Study ID Numbers: EKBB 69/04
Study First Received: September 16, 2009
Last Updated: September 16, 2009
Health Authority: Switzerland: Ethikkommission

Keywords provided by University Hospital, Basel, Switzerland:
satiety peptides
GLP-1
PYY
ghrelin
appetite profile
Sweetening Agents

ClinicalTrials.gov processed this record on April 17, 2014